Nucleic acids encoding CD100 molecules
    1.
    发明授权
    Nucleic acids encoding CD100 molecules 失效
    编码CD100分子的核酸

    公开(公告)号:US07700102B2

    公开(公告)日:2010-04-20

    申请号:US10320769

    申请日:2002-12-16

    IPC分类号: A61K39/395

    摘要: Isolated nucleic acid molecules encoding novel CD100 molecules which stimulate a leukocyte response, such as a B cell response, including B cell aggregation, B cell differentiation, B cell survival, and/or T cell proliferation are disclosed. These novel molecules have a certain homology to semaphorins, proteins which are growth cone guidance molecules that are critical for guiding growing axons of neurons to their targets. In addition to isolated nucleic acids molecules, antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced are also described. The invention further provides isolated CD100 proteins, fusion proteins and active fragments thereof. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译: 公开了编码新的CD100分子的分离的核酸分子,其刺激白细胞应答,例如B细胞应答,包括B细胞聚集,B细胞分化,B细胞存活和/或T细胞增殖。 这些新型分子与semaphorins具有一定的同源性,蛋白质是生长锥形引导分子,对于将神经元的生长轴突引导到其靶点至关重要。 还描述了分离的核酸分子,含有本发明的核酸分子的重组表达载体的反义核酸分子,已经引入了表达载体的宿主细胞。 本发明还提供了分离的CD100蛋白,融合蛋白及其活性片段。 还提供了利用本发明组合物的诊断和治疗方法。

    Use of anti-cd100 antibodies
    6.
    发明申请
    Use of anti-cd100 antibodies 有权
    使用抗cd100抗体

    公开(公告)号:US20060233793A1

    公开(公告)日:2006-10-19

    申请号:US10544031

    申请日:2004-02-02

    IPC分类号: A61K39/395

    CPC分类号: C07K16/2803 A61K2039/505

    摘要: The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.

    摘要翻译: 本发明涉及使用BD16和/或BB18抗CD100抗体或其嵌合或人源化或人形式或其片段用于治疗或诊断中枢神经系统疾病,特别是髓鞘病症或 影响少突胶质细胞的疾病,如多发性硬化或HTLV-1相关性脊髓病或外周髓鞘细胞。

    Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
    7.
    发明授权
    Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells 失效
    抗CD71单克隆抗体及其用于治疗恶性肿瘤细胞的用途

    公开(公告)号:US08409573B2

    公开(公告)日:2013-04-02

    申请号:US11922025

    申请日:2006-06-14

    IPC分类号: A61K39/00

    摘要: The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells.

    摘要翻译: 本发明提供了新颖的抗CD71单克隆抗体,特别是小鼠 - 人嵌合抗CD71单克隆抗体,其有利地与效应细胞相关联,用于触发ADCC机制。 抗CD71抗体以及含有它们的药物组合物可用于抑制增殖和/或杀死恶性肿瘤细胞,特别是转移性皮肤和葡萄膜黑素瘤细胞。